Loading clinical trials...
Loading clinical trials...
Conditions
Interventions
Ivosidenib,Venetoclax,gilteritinib,Selinexor
Locations
1
China
Blood Hospital
Tianjin, China
Start Date
February 22, 2024
Primary Completion Date
January 30, 2026
Completion Date
June 30, 2026
Last Updated
August 6, 2025
NCT05039801
NCT05053971
NCT07350863
NCT06189391
NCT04973605
NCT05281471
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions